SC
RPRX icon

Samlyn Capital’s Royalty Pharma RPRX Stock Holding History

Samlyn Capital’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-726,018
Closed -$18.5M – 105
2024
Q4 		$18.5M Buy
+726,018
New +$19.3M 0.28% 78
2020
Q3 		– Sell
-426,000
Closed -$20.7M – 169
2020
Q2 		$20.7M Buy
+426,000
New +$21.1M 0.38% 72

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Samlyn Capital's RPRX Position: Q1 2025 in Review

Samlyn Capital sold out of Royalty Pharma (RPRX) in Q1 2025, closing a stake of 726,018 shares — an estimated $18.5M sold.

Samlyn Capital first reported a position in RPRX in Q2 2020 and held it in 2 quarters. The position peaked at $20.7M in Q2 2020. 447 funds tracked by Wall St. Rank hold RPRX as of Q1 2025.

  • Samlyn Capital reported no remaining Royalty Pharma position as of Q1 2025 after selling out during the quarter.
  • Samlyn Capital sold 726,018 Royalty Pharma shares in Q1 2025, an estimated $18.5M.
  • Samlyn Capital first reported a position in Royalty Pharma in Q2 2020 and held it in 2 quarters.
  • Samlyn Capital's Royalty Pharma position peaked at $20.7M in Q2 2020.
  • 447 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2025.

Based on Samlyn Capital's 13F filing for Q1 2025, filed 15 May 2025.